Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases
Open Access
- 31 July 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Eye
- Vol. 34 (8), 1341-1356
- https://doi.org/10.1038/s41433-020-0770-y
Abstract
Anti-vascular endothelial growth factors (anti-VEGF) have become the most common treatment modality for many retinal diseases. These include neovascular age-related macular degeneration (n-AMD), proliferative diabetic retinopathy (PDR) and retinal vein occlusions (RVO). However, these drugs are administered via intravitreal injections that are associated with sight-threatening complications. The most feared of these complications is endophthalmitis, a severe infection of the eye with extremely poor visual outcomes. Patients with retinal diseases typically have to undergo multiple injections before achieving the desired therapeutic effect. Each injection incurs the risk of the sight-threatening complications. As such, there has been great interest in developing sustained delivery platforms for anti-VEGF agents to the posterior segment of the eye. In recent years, there have been various strategies that have been conceptualised. These include non-biodegradable implants, nano-formulations and hydrogels. In this review, the barriers of drug delivery to the posterior segment of the eye will be explained. The characteristics of an ideal sustained delivery platform will then be discussed. Finally, the current available strategies will be analysed with the above-mentioned characteristics in mind to determine the advantages and disadvantages of each sustained drug delivery modality. Through the above, this review attempts to provide an overview of the sustained delivery platforms in their various phases of development.Keywords
Funding Information
- A*STAR | Institute of Molecular and Cell Biology (IAF-PP H17/01/a0/013, IAF-PP H17/01/a0/013, IAF-PP H17/01/a0/013)
- A*STAR | Institute of Materials Research and Engineering
- NTU | Lee Kong Chian School of Medicine, Nanyang Technological University
This publication has 103 references indexed in Scilit:
- Liposomes and nanotechnology in drug development: focus on ocular targetsInternational Journal of Nanomedicine, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration: Twelve-Month Results of the DENALI StudyOphthalmology, 2012
- Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration: Twelve-month MONT BLANC Study ResultsOphthalmology, 2012
- A novel co-culture model of the blood-retinal barrier based on primary retinal endothelial cells, pericytes and astrocytesExperimental Eye Research, 2012
- Nanospheres Delivering the EGFR TKI AG1478 Promote Optic Nerve Regeneration: The Role of Size for Intraocular Drug DeliveryACS Nano, 2011
- Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not RequiredJAMA Ophthalmology, 2009
- PREPARATION, CHARACTERIZATION, AND IN VIVO EVALUATION OF NANOLIPOSOMES-ENCAPSULATED BEVACIZUMAB (AVASTIN) FOR INTRAVITREAL ADMINISTRATIONRetina, 2009
- Effects of PEG hydrogel crosslinking density on protein diffusion and encapsulated islet survival and functionJournal of Biomedical Materials Research Part A, 2008
- INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTIONRetina, 2008